We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Editas (EDIT) Up 9.3% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Editas Medicine (EDIT - Free Report) . Shares have added about 9.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Editas due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Editas' Earnings Rise Y/Y in Q3, EDIT-101 in Focus
Editas delivered earnings of 12 cents per share in the third quarter of 2020, reversing the year-ago quarter’s loss of 66 cents. The Zacks Consensus Estimate was of a loss of 66 cents per share.
Collaboration, and other research and development revenues comprising the company’s top line came in at $62.8 million in the reported quarter, substantially up from the year-ago quarter’s $4 million. The top line also comprehensively beat the Zacks Consensus Estimate of $7 million.
Quarter in Detail
Research and development expenses were $33.9 million, up 49.3% from the year-ago figure due to increased expenses related to the development of EDIT-101.
General and administrative expenses increased 26.7% to $19.9 million owing to higher professional service expenses and personnel costs.
How Have Estimates Been Moving Since Then?
It turns out, estimates review flatlined during the past month. The consensus estimate has shifted 8.69% due to these changes.
VGM Scores
At this time, Editas has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Editas (EDIT) Up 9.3% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Editas Medicine (EDIT - Free Report) . Shares have added about 9.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Editas due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Editas' Earnings Rise Y/Y in Q3, EDIT-101 in Focus
Editas delivered earnings of 12 cents per share in the third quarter of 2020, reversing the year-ago quarter’s loss of 66 cents. The Zacks Consensus Estimate was of a loss of 66 cents per share.
Collaboration, and other research and development revenues comprising the company’s top line came in at $62.8 million in the reported quarter, substantially up from the year-ago quarter’s $4 million. The top line also comprehensively beat the Zacks Consensus Estimate of $7 million.
Quarter in Detail
Research and development expenses were $33.9 million, up 49.3% from the year-ago figure due to increased expenses related to the development of EDIT-101.
General and administrative expenses increased 26.7% to $19.9 million owing to higher professional service expenses and personnel costs.
How Have Estimates Been Moving Since Then?
It turns out, estimates review flatlined during the past month. The consensus estimate has shifted 8.69% due to these changes.
VGM Scores
At this time, Editas has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the lowest quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Editas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.